INTRODUCTION {#S1}
============

Knowledge of genetic predictors of disease severity may be useful as markers for detection of TB patients at risk of developing a severe TB disease. Revealing the mechanisms of severe disease in these patients may provide molecular targets for new clinical interventions. It is well established that functional genetic polymorphisms in specific molecules of the immune/inflammatory response increase the likelihood of progression from *M. tuberculosis* infection to active pulmonary TB ([@R1]--[@R7]). Active TB may evolve into severe lung disease, or even to extra-pulmonary disease if left untreated ([@R1]--[@R7]). We propose that expression of severe pulmonary TB disease is genetically controlled.

Human host-encoded susceptibility to expression of severe pulmonary TB may involve: (i) the spread of infection beyond a critical number of cells because of a failing immune response against this challenge ([@R4]--[@R7]); and (ii) an excessive inflammatory response (hyper-inflammatory response), resulting in extensive inflammation-caused tissue damage ([@R3]). These mechanisms are not necessarily mutually exclusive. We previously reported that a functional single nucleotide polymorphism (SNP) located in position -2518 of the enhancing promoter region of the *macrophage chemoattractant protein (MCP)-1* gene (the genotype *GG*) is associated with the expression of active TB disease in humans ([@R1]). Our *ex vivo* and *in vitro* studies indicated that increased MCP-1 production in response to infection is driving the expression of disease in carriers of that susceptibility genotype ([@R1], [@R2]). MCP-1 is a potent chemoattractant of macrophages that, in excess, down-regulates IL-12p40 production ([@R1], [@R8]--[@R10]), and up-regulates matrix metalloproteinase (MMP)-1 production by these cells in response to *M. tuberculosis* antigens, *in vivo* and *in vitro* ([@R2]). IL-12p40 is a subunit of two cytokines that are essential in the development of cellular immunity against TB, IL-12 and IL-23 ([@R7]). On the other hand, human MMP-1 is a potent collagenase, and collagen is an essential component of the granulomatous matrix over which cells (such as macrophages, T-cells, etc.) become organized to form granulomas and also a very important component of the lung matrix ([@R2], [@R11]). Thus, MMP-1 may be involved in liquefaction of mature granulomas. MMP-1 may also oppose to granuloma formation and maturation. MCP-1, MMP-1 and MMP-9 may contribute to non-granulomatous damage of lung tissue in patients affected by TB. Given that granulomas may serve to enclose infected cells and free bacteria in a confined environment, we and other investigators hypothesize that excessive MMP-1 levels may promote the spread of infection and inflammation ([@R2], [@R12]--[@R17]).

In search for genetic modifiers of the -2518 *MCP-1* genotype *GG*, we reported that Hispanics with Amerindian ancestry carrying the two-locus genotype -2518 *MCP-1 GG* -1607 *MMP-1 2G/2G* are at a significant increased chance of progression from *M. tuberculosis* infection to active TB disease ([@R2]). Of note, the -2518 *MCP-1* allele *G* and the -1607 *MMP-1* allele *2G* creates a transcription activator-like effector (TALE) binding site for PREP1/PBX2 transcription factor complexes ([@R18], [@R19]), and increases the rate of transcription of the *MCP-1* gene, which is active in TB ([@R1], [@R2], [@R20]). Likewise, the -1607 *MMP-1* allele *2G*, which consists of the insertion of a guanine at position -1607 (the allele *2G*), creates an Ets-1 transcription factor binding site ([@R21], [@R22]), and enhances expression of the gene in normal and tumor cells, and in active TB ([@R21], [@R22]).

Whether the two-locus susceptibility genotype -2518 *MCP-1 GG* and -1607 *MMP-1 2G/2G* may also influence the expression of a more severe disease is unknown. Thus, in this study we address this question. We also conducted *ex vivo* and *in vitro* experiments to unveil potential mechanisms of disease severity in carriers of this two-locus susceptibility genotype. Data from this study could guide the development of new therapeutic approaches to overcome host-encoded deleterious hyper-inflammatory response to *M. tuberculosis* infection and expression of severe pulmonary TB. Here, we are also demonstrating that excessive MMP-1 may potentiate the MCP-1 and *M. tuberculosis*-induced inflammatory response through activation of protease activated receptor (PAR)-1, and thereby increases the likelihood of developing a severe TB disease.

RESULTS {#S2}
=======

Demographic and clinical features of TB cases studied {#S3}
-----------------------------------------------------

We recruited *de novo* 224 patients with TB that met the enrollment criteria and were tightly followed through the directly observed therapy program (DOT), ens uring adherence to therapy. We did not see differences in the proportion of males and females, nor in the mean age between groups ([Table 1](#T1){ref-type="table"}). None of the patients self-reported consumption of alcohol or tobacco. All of them were of low socioeconomic status and Peruvian Mestizo to the third generation (an admixture of mainly Amerindian and Spaniards). All of the patients were recruited in similar geographical areas, where they had lived for more than 2 years, making it more likely that they were infected by the same bacterial strains circulating in the region. They were all BCG-vaccinated, and had a disease confined to the lungs of no more than 3 months of evolution. We did not see differences in duration of disease (the length of time that passed since the first symptom was noticed by the patient to the time of sampling) ([Table 1](#T1){ref-type="table"}). To test for differences in the admixture of TB cases stratified according to genotypes, we genotyped 42 genomic controls and compared the allele frequencies across strata using a chi^2^ test. We used these chi^2^ values to calculate a λ value of admixture as we did before ([@R1], [@R2]). The λ value of admixture was 0.95 ([Table S1](#SD1){ref-type="supplementary-material"}). As this was close to 1, we concluded that there was not a significant difference in the level of admixture between TB cases in each stratum.

The two-locus genotype -2518 *MCP-1 GG* and -1607 *MMP-1 2G/2G* is associated with expression of severe TB disease {#S4}
------------------------------------------------------------------------------------------------------------------

To assess the severity of disease, we modified previously published severity scores developed to capture clinical information available in low-resource countries (23--26; [Table 2](#T2){ref-type="table"}). An expert physician classified the patients into two categories: severe or non-severe disease, according to the clinical characteristics exposed in [Table 2](#T2){ref-type="table"}. Following this analysis, we proceeded to assign scores and classified the cases according to whether their scores were above the median (severe disease) or were ≤ the median values obtained (non-severe disease). The median score was 44. We obtained a significant agreement between the clinical diagnosis of severe disease and the classification according to the severity score (κ coefficient = 0.83). Disagreements were observed in 20 cases with scores ≤ 44. Of note, the partial scores obtained from the assessment of clinical signs and symptoms and that obtained from the assessment of posteroanterior full-size chest X-rays were consistent, since a significant direct (positive) correlation was observed between them (Spearman's Rho = 0.83; p = 0.00001).

There was a greater proportion of cases with severity scores higher than the median among those TB cases carrying the two-locus genotype -2518 *MCP-1 GG* -1607 *MMP-1 2G/2G*, than in TB cases carrying any other relevant combination of genotypes at those two loci ([Table 1](#T1){ref-type="table"}). There was a significant difference in BMI values across stratum ([Table 1](#T1){ref-type="table"}). The proportion of TB cases with BMI \< median was higher among carriers of the two-locus genotype -2518 *MCP-1 GG* -1607 *MMP-1 2G/2G* ([Table 1](#T1){ref-type="table"}).

We run a logistic regression analysis to assess whether the main or joint effects of the -2518 *MCP-1* genotype *GG* and the -1607 *MMP-1* genotype *2G/2G* would predict the severity of disease, adjusting for age and gender ([Table 3](#T3){ref-type="table"}). We used the severity score as a surrogate marker of disease severity, as explained in materials and methods. We observed that the two-locus genotype -2518 *MCP-1* genotype *GG* -1607 *MMP-1* genotype *2G/2G* was significantly associated with expression of a severe TB disease, with strong point estimates of association ([Table 3](#T3){ref-type="table"}). None of the other two-locus genotypes, or age and gender contributed significantly to the expression of severe TB disease in this sample ([Table 3](#T3){ref-type="table"}). The observed model did not differ from that predicted (Pearson goodness-of-fit test, [Table 3](#T3){ref-type="table"}). Using a second analytical approach, we corroborated our findings and observed significant differences in the mean of severity scores between groups ([Table 4](#T4){ref-type="table"}). The carriers of the two-locus -2518 *MCP-1 GG* -1607 *MMP-1 2G/2G* had the highest score ([Table 4](#T4){ref-type="table"}). Six TB cases carrying the two-locus -2518 *MCP-1 GG* -1607 *MMP-1 2G/2G* underwent surgery to remove damaged lung tissue versus none in the groups of carriers of any other combination of genotypes at these two loci.

Given all of this evidence, we concluded that adult TB cases carrying the two-locus genotype -2518 *MCP-1 GG* and -1607 *MMP-1 2G/2G* express a more severe TB disease than carriers of any other relevant combination of genotypes at these two loci.

TB patients carrying the two-locus genotype -2518 *MCP-1 GG* -1607 *MMP-1 2G/2G* expressed a delayed response to standardized treatment and extensive fibrosis surrounding cavities and bronchiectasis at the end of the treatment {#S5}
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

We asked whether disease severity, which reflects excessive tissue damage, will influence the response to the standardized TB treatment. Most of our TB cases observed a sputum smear test conversion from positive to negative at the second month of treatment. In contrast, we observed that 29.6% of TB patients carrying the two-locus genotype -2518 *MCP-1 GG* and -1607 *MMP-1 2G/2G* experienced a significant delayed response to treatment ([Table 5](#T5){ref-type="table"}). The test for homogeneity of the odds and the score Test for Trend in Odds indicate the presence of a dose-response relationship, were carrying the genotypes -2518 *MCP-1 GG* and the -1607 *MMP-1 2G/2G* conferred the highest odds of a sputum test conversion from positive to negative at more than 3 months (mean ± SD = 3.7 ± 0.6), a delayed response to treatment according to the WHO ([Table 5](#T5){ref-type="table"}). At the end of the treatment, a greater proportion of TB cases, all carrying the two-locus genotype -2518 *MCP-1 GG* -1607 *MMP-1 2G/2G*, had more than 2/3 of lung parenchyma compromised by fibrotic lesions than carriers of any other genotypes, which was reflected by the presence of Dyspnoea (difficulty breathing). Thirty three out of 71 TB cases carrying the susceptibility two-locus genotype (83%) versus 18 out of 153 TB cases (37.8%) in carriers of any other combination of genotypes expressed those permanent lesions (OR = 6.5, 95% CI = 3.14--13.6; chi-squared= 33.23, p \< 0.00001). Lung fibrosis was mainly observed surrounding cavities and bronchiectasis.

Carriers of the two-locus genotype -2518 *MCP-1 GG* -1607 *MMP-1 2G/2G* express the highest levels of MMP-9 {#S6}
-----------------------------------------------------------------------------------------------------------

Using immunohistochemistry (IHC), we assessed the levels of MCP-1, MMP-1, and MMP-9 expression by alveolar macrophages in lung tissue from those six TB cases that required surgery to remove damaged tissue. MMP-9 was tested because, in the Zebra fish model of tuberculosis, MMP-9 was shown to drive the recruitment of monocytes to the granulomatous inflammatory foci, where these cells were exposed and infected with *M. marinum*, resulting in a significant increase in the burden of infected cells ([@R27]). Because of the extensive lung damage observed, we focused our analysis on granulomas located in areas of lung parenchyma surrounding extensive necrotic areas. We observed several macrophages, and other cells (i.e. lung epithelial cells) expressing copious amounts of MCP-1, MMP-1, and MMP-9 in these tissues ([Fig. 1](#F1){ref-type="fig"}). The disease tissue slices showed multiple dark purple cells, which could be interpreted as macrophages (red for CD68) expressing MCP-1, MMP-1, MMP-9 (blue for each factor). We could not assess whether those levels observed in lung tissues were higher in carriers of the -2518 *MCP-1 GG* -1607 *MMP-1 2G/2G* than in carriers of any other combination of genotypes at these two loci because of the lack of tissues from the latter groups. Hence, to further determine whether genotypes will correlate with phenotypes in these TB cases we measured the serum levels of MCP-1 and plasma levels of MMP-1 and MMP-9 ([Fig. 2](#F2){ref-type="fig"}).

Thirty randomly selected cases per each of the four relevant -2518 *MCP-1* -1607 *MMP-1* two-locus genotypes, and 20 healthy controls (only as reference) were assessed. MMP-9 was significantly over expressed in TB patients carrying the two-locus genotype -2518 *MCP-1 GG* and -1607 *MMP-1 2G/2G*, as compared to the levels of MMP-9 in carriers of any other combination of genotypes at these two loci ([Fig. 2](#F2){ref-type="fig"}). A less significant increase in MCP-1 and MMP-1 was also observed in carriers of the two-locus genotype -2518 *MCP-1 GG* -1607 *MMP-1 2G/2G*, when compared to the levels of these factors in carriers of other combinations of genotypes at these two loci ([Fig. 2](#F2){ref-type="fig"}). Controls had only normal levels of MMP-9 (24.760 ± 13.050 ng/ml) and MMP-1 (6.12 ± 2.76 ng/ml) in plasma, and MCP-1 (563 ± 328 pg/ml) in serum. Furthermore, we obtained significant positive correlations between MCP-1 levels (Spearman's Rho = 0.91; p \< 0.00001) or MMP-1 levels (Spearman's Rho = 0.93; p \< 0.00001) or MMP-9 levels (Spearman's Rho = 0.9; p \< 0.00001) and the scores in TB cases carrying the two-locus genotype -2518 *MCP-1 GG* -1607 *MMP-1 2G/2G*. All together, this indicates that carriers of the susceptibility genotype have the higher severity scores and express the higher levels of MCP-1, MMP-1 and MMP-9.

*In vitro* studies revealed underlying mechanisms of increased MMP-9 {#S7}
--------------------------------------------------------------------

Given that we observed the highest plasma levels of MMP-9 in TB patients carrying the two-locus genotype -- 2518 *MCP-1 GG* -1607 *MMP-1 2G/2G*, we reasoned that this might result from more complex preceding molecular events, where MCP-1 and MMP-1 were involved. We used *in vitro* exposure of human THP-1 monocytic cells to sonicated H37Rv *M. tuberculosis* to model the exposure of massively recruited monocytes to the lung inflammatory foci during TB-induced inflammatory response ([@R28]--[@R31]). We observed that exposure of THP-1 cells to sonicated H37Rv *M. tuberculosis* for 24 hrs caused a significant increase in the expression of MCP-1, MMP-1, and MMP-9 ([Fig. 3](#F3){ref-type="fig"}). In contrast, this stimulus inhibited the expression of tissue inhibitor of metalloproteinase (TIMP)-1, -2, -3, and 4 ([Fig. 3](#F3){ref-type="fig"}). To test the notion that MCP-1 increases MMP-9 production, we activated THP-1 cells with sonicated H37Rv *M. tuberculosis* and inhibited CCR2 with the compound RS504393 ([Fig. 3](#F3){ref-type="fig"}, Panel 1). MCP-1 effects are likely inhibited by this compound since CCR2 is the only receptor for MCP-1 ([@R32]). MMP-9 mRNA expression in response to the sonicated H37Rv *M. tuberculosis* stimuli was significantly decreased by this CCR2 inhibiting compound ([Fig. 3](#F3){ref-type="fig"}, Panel 1). MCP-1 and MMP-1 mRNA were also significantly down-regulated by this CCR2 inhibitor ([Fig. 3](#F3){ref-type="fig"}, Panel 1). Although the expression of natural inhibitors of MMPs (TIMP-1, -2, -3, and -4) was poor, as compared to that of MMP-1 and MMP-9, RS504393 appeared to slightly counteract the inhibitory effect of the sonicated H37Rv *M. tuberculosis* exposure on TIMPs expression ([Fig. 3](#F3){ref-type="fig"}, Panel 1). We next investigated whether inhibition of MMP-1 would provide similar results. Using the 4-Aminobenzoyl-Gly-Pro-D-Leu-D-Ala hydroxamic peptide (at 1 μM concentration) to inhibit MMP-1 functions we could also down-regulate MMP-9 ([Fig. 3](#F3){ref-type="fig"}, Panel 2). Although MCP-1 was not significantly down-regulated, MMP-1 expression was significantly inhibited by addition of the 4-Aminobenzoyl-Gly-Pro-D-Leu-D-Ala hydroxamic peptide to cultures of THP-1 cells activated with sonicated H37Rv *M. tuberculosis* ([Fig. 3](#F3){ref-type="fig"}, Panel 2). TIMP expression was not significantly modulated by this MMP-1 inhibitor ([Fig. 3](#F3){ref-type="fig"}, Panel 2).

MMP-1 may activate PAR-1 expression on monocytes/macrophages in tuberculosis to induce MCP-1, MMP-1, and MMP-9 expression {#S8}
-------------------------------------------------------------------------------------------------------------------------

Given the fact that MMP-1 can activate protease-activated receptor (PAR)-1 ([@R33]), we asked whether this pathway might operate in tuberculosis. Alveolar macrophages are the first line of defense in the lungs and the initiators of peripheral monocyte recruitment into the lungs' inflammatory foci ([@R28]--[@R31]). Alveolar macrophages express CD14 and CD68 markers ([@R34]--[@R36]). IHC analysis of PAR-1 expression revealed that human alveolar macrophages in normal lungs constitutively express PAR-1. Of note, there were some macrophages in the interstitium of normal tissues (the tissue and space around the air sacs of the lung); we reasoned that this might be a displacement artifact produced while processing the samples ([Fig. 4](#F4){ref-type="fig"}, panel 1). Few macrophages in lung tissues from individuals with severe TB disease do express PAR-1 ([Fig. 4](#F4){ref-type="fig"}, panel 2). Indeed, some dark purple cells could be observed which could be interpreted as macrophages (red for CD68) expressing PAR-1 (blue). Images taken at lower magnification of tissues presented in [figure 1](#F1){ref-type="fig"}, panel 2, corroborates this statement ([Fig. S1](#SD2){ref-type="supplementary-material"}).

PAR-1 was also expressed by epithelial cells in normal and disease lungs ([Fig. 4](#F4){ref-type="fig"}). Low PAR-1 expression in diseased tissues might result from the enzymatic activity of several proteases in the lung milieu of these severe cases that may digest several proteins, including PAR-1. In conjunction with this, PAR-1 may have been down-regulated in response to activation by thrombin or/and MMP-1. Of note, the same anti-PAR-1 antibody was used to stain normal lung tissue, and both experiments were done simultaneously. Thus, lack of specificity of the antibody does not explain our results.

MMP-1 may activate PAR-1 in THP-1 cell exposed to *M. tuberculosis* sonicate {#S9}
----------------------------------------------------------------------------

To test the whether MMP-1 activates PAR-1 in THP-1 cells exposed to sonicated *M. tuberculosis* H37Rv, we took advantage of the fact that PAR-1 is a G-coupled protein receptor and that as such, PAR-1 undergoes recycling upon activation by thrombin or MMP-1 ([@R33]). We focused our analysis of PAR-1 expression in THP-1 cells expressing a phenotype close to that of macrophages. We observed by FACS analysis, that a low proportion of quiescent THP-1 cells expressed CD14, and that a very low proportion of these cells expressed CD16 ([Fig. 5](#F5){ref-type="fig"}, Panels 1 and 2, Section A). CD14-positive/CD16-negative THP-1 cells also expressed CD68 (data not shown). Exposure of THP-1 cells to sonicated H37Rv *M. tuberculosis* mainly induced their differentiation into CD14-positive/CD16-negative cells ([Fig. 5](#F5){ref-type="fig"}, Panels 1 and 2, Section B) ([@R34]--[@R36]). Interestingly, none of the compounds or peptides used perturbed the differentiation of THP-1 cells into CD14-positive/CD16-negative cells ([Fig. 5](#F5){ref-type="fig"}, Panels 1 and 2, Section C). We next gated into CD14-positive/CD16-negative THP-1 cells to determine whether PAR-1 expression is regulated by exposure of these cells to sonicated H37Rv *M. tuberculosis* ± MMP-1 inhibitor 4-Aminobenzoyl-Gly-Pro-D-Leu-D-Ala hydroxamic peptide ([Fig. 5](#F5){ref-type="fig"}, Panel 1, Sections D, E, and F). We observed that 27% of the gated CD14-positive/CD16-negative quiescent THP-1 cells expressed PAR-1 ([Fig. 5](#F5){ref-type="fig"}, Panel 1, Section D). Exposure of THP-1 cells to sonicated H37Rv *M. tuberculosis* significantly down-regulated the expression of PAR-1 to 11.3% (D versus E: OR = 2.96, 95% CI = 2.6--3.3, p \< 0.00001; [Fig. 5](#F5){ref-type="fig"}, Panel 1). The addition of MMP-1 inhibitor to *M. tuberculosis* stimulated THP-1 cells preserved the expression of PAR-1 in approximately 22% of cells (F versus E: OR = 2.2, 95% CI = 1.95--2.4, p \< 0.00001; [Fig. 5](#F5){ref-type="fig"}, Panel 1).

We then asked whether the CCR2 inhibitor RS504393 would provide similar results since MCP-1 activates CCR2 and through this it potentiates the expression of MMP-1 by *M. tuberculosis*-stimulated THP-1 cells ([Fig. 3](#F3){ref-type="fig"}, Panel 1). Approximately 50% of the gated CD14-positive/CD16-negative quiescent THP-1 cells expressed PAR-1 ([Fig. 5](#F5){ref-type="fig"}, Panel 2, Section D). Once again, exposure of THP-1 cells to sonicated H37Rv *M. tuberculosis* significantly down-regulated (to 3.39%) the expression of PAR-1 (D versus E: OR = 28.6, 95% CI = 20.2--41.1, p \< 0.00001; [Fig. 5](#F5){ref-type="fig"}). The addition of CCR2 inhibitor to *M. tuberculosis*-stimulated THP-1 cells preserved the expression of PAR-1 in approximately 35% of the cells (F versus E: OR = 15.24, 95% CI = 11.1--21.5; p \< 0.00001; [Fig. 5](#F5){ref-type="fig"}, Panel 2). Notably, THP-1 cells cultured under any of the aforementioned conditions did not express thrombin (data not shown). Hence, we considered that this results added evidence that MMP-1 could be activating PAR-1 in this *in vitro* system and inducing recycling of this receptor. Since we partially recovered PAR-1 cell membrane expression by treating *M. tuberculosis*-antigen-activated THP-1 cells with a MMP-1 or a CCR2 inhibitor, we do not exclude the possibility that other macrophage proteases might be acting on PAR-1 as well.

Treatment of H37Rv *M. tuberculosis*-infected THP-1 cells with PAR-1 inhibitor SCH79797 down-regulates MMP-1 induced MCP-1, MMP-1 and MMP-9 {#S10}
-------------------------------------------------------------------------------------------------------------------------------------------

We first used the SCH79797 PAR-1 inhibitor to test whether PAR-1 inhibition regulates the expression of MCP-1, MMP-1, MMP-9, and the TIMPs by *M. tuberculosis*-stimulated THP-1 cells. We observed that PAR-1 inhibitor SCH79797, at nanomolar concentrations (50 nM), potently down-regulated MCP-1, MMP-1, and MMP-9 mRNA expression by THP-1 cells stimulated with sonicated H37Rv *M. tuberculosis* ([Fig. 6](#F6){ref-type="fig"}, Panel 1). This inhibitor did not significantly regulate the expression of the TIMPs ([Fig. 6](#F6){ref-type="fig"}, Panel 1). To confirm that MMP-1 activates PAR-1, we added exogenous human purified MMP-1 (hMMP-1) to *M. tuberculosis*-stimulated THP-1 cells and observed that exogenous MMP-1 increased MCP-1, MMP-1, and MMP-9 expression to levels that were higher than those observed in cultures of THP-1 cells stimulated with sonicated H37Rv *M. tuberculosis* alone ([Fig. 6](#F6){ref-type="fig"}, Panel 2). Addition of PAR-1 inhibitor to THP-1 cells stimulated with sonicated H37Rv *M. tuberculosis* in the presence of hMMP-1 significantly decreased the expression of MCP-1, MMP-1, and MMP-9 ([Fig. 6](#F6){ref-type="fig"}, Panel 1). Thus, we confirmed that MMP-1 activation of PAR-1 regulates the expression of MCP-1, MMP-1, and MMP-9 by *M. tuberculosis*-stimulated THP-1 cells.

Based on the results described above, we concluded that PAR-1 activation by MMP-1 emerged as a key event in *M. tuberculosis*-induced and MCP-1-potentiated inflammatory response *in vitro*. Thus, we further tested the effect of SCH79797 PAR-1 inhibitor on the expression of MCP-1, MMP-1, MMP-9 and additional 31,000 annotated genes in *M. tuberculosis* H37Rv-infected THP-1 cells, using an whole genome expression microarray.

We first selected those genes regulated by H37Rv *M. tuberculosis* infection. To do so, we compared the gene expression profiles of infected cells and non-infected cells and selected those genes significantly regulated, according to our stringent parameters ([Table 6](#T6){ref-type="table"}). We then followed the effect of treatment on the expression of those genes by comparison of infected cells treated with SCH79797 (50 nM) versus infected cells untreated. Among those genes significantly regulated by PAR-1 inhibitor treatment were our primary target genes *MCP-1* (*CCL2*), *MMP-1*, and *MMP-9* ([Table 6](#T6){ref-type="table"}). In addition, *IL-7 receptor* (*IL7R*), *Toll-like receptor 8* (*TLR8*), and SPP-1 genes were also modulated by this treatment ([Table 6](#T6){ref-type="table"}). Thus, we confirmed the down-regulation of MCP-1, MMP-1 and MMP-9 by PAR-1 inhibitor in *M. tuberculosis* infected cells. Interestingly, PAR-1 treatment did not significantly modify the expression TNFα in response to infection ([Table 6](#T6){ref-type="table"}), which is required to mount a protective immune response against *M. tuberculosis* ([@R37]). In addition, CD14 gene expression was up-modulated by *M. tuberculosis* infection, in concordance with the notion that infection causes maturation of THP-1 ([Table 6](#T6){ref-type="table"}) ([@R38]). PAR-1 treatment of THP-1 cells did not modify significantly this trend ([Table 6](#T6){ref-type="table"}). We further confirmed the down-regulation of MCP-1, MMP-1 and MMP-9 by PAR-1 inhibitor testing the concentrations of functional proteins in supernatants of THP-1 cells infected with *M. tuberculosis* H37Rv ([Table 7](#T7){ref-type="table"}).

We also analyzed those genes that were not regulated by infection *per se*, but were significantly regulated by PAR-1 treatment in infected cells. Of note, CCR2 (the receptor of MCP-1) and TIMP3 were differentially and significantly down-regulated by PAR-1 treatment of those cells ([Table S2](#SD1){ref-type="supplementary-material"}). We did not observed significant differences in the CFU in infected THP-1 cells treated with PAR-1 inhibitor or untreated ([Table 7](#T7){ref-type="table"}). In our model, PAR-1 plays a significant role in the amplification of the inflammatory response to *M. tuberculosis* infection ([Fig. S2](#SD3){ref-type="supplementary-material"}).

DISCUSSION {#S11}
==========

Our studies in human populations combined with our *ex vivo* analysis of tissues from TB cases, and our *in vitro* model using the human THP-1 monocytic cell line, led us to conclude that the -2518 *MCP-1* genotype *GG* and the -1607 *MMP-1* genotype *2G/2G* are key genetic loci associated with the expression of severe TB disease. The presence of both genotypes increases by 13-fold the chance of developing severe TB disease, by 3.864-fold the chance of a delayed sputum conversion from positive to negative, and by 6.5-fold the chance of developing extensive areas of lung fibrosis. Moreover, the two-locus genotype -2518 *MCP-1 GG* -1607 *MMP-1 2G/2G* operates with high penetrance in this population since 83% of the carriers expressed severe disease. Neither the -2518 *MCP-1* genotype *GG* nor the -1607 *MMP-1* genotype *2G/2G* alone were sufficient to produce a severe disease. Interestingly, a higher proportion of TB patients carrying the susceptibility two-locus genotype -2518 *MCP-1 GG* -1607 *MMP-1 2G/2G* have had BMI values at first visit lesser than the median BMI value of the entire sample. Interestingly, weight loss is *per se* a key marker of severity of TB disease in animal models ([@R39]). All together, our observations have important implications when the interest is to detect, as early as possible, those persons who are at increased chance of developing a severe TB disease, may remain contagious for a longer period than any other TB case, and will develop a poor health related-quality of life. We must remember that these TB cases were tightly followed up which may have decreased the chance of abandonment of treatment and progression to a potentially lethal illness. This may also have implications for the treatment time required to attain sputum smear test conversion in TB cases infected with multi-drug resistant (MDR)-*M. tuberculosis* strains and the increased mortality observed among them.

Six TB cases in carriers of the two-locus genotype -2518 *MCP-1 GG* -1607 *MMP-1 2G/2G* expressing severe disease (score \> 44) underwent surgery to remove damaged lung tissue versus none in the groups of carriers of any other combination of genotypes at these two loci. The IHC analysis of these lung tissues revealed macrophages expressing copious amounts of MCP-1/CCL2, MMP-1, and MMP-9. Cell of other lineages (CD68-negative) were also present in the lesions and expressing these factors, indicating a possible crosstalk between macrophages and perhaps, lung epithelial cells. Our IHC analysis is in agreement with results from a genome-wide comparison of gene expression in human granulomatous lesions ([@R40]). Access to their database allowed us to rank the genes according to the magnitude of the ratios and observed that MCP-1/CCL2, MMP-1 and MMP-9 were also among the most significantly up-regulated genes in human granulomatous lesions ([@R40]).

We tested serum and plasma samples and observed the highest serum levels of MCP-1, and the highest plasma levels of MMP-1 and MMP-9 in carriers of the two-locus genotype -2518 *MCP-1 GG* -1607 *MMP-1 2G/2G* as compared to levels of these molecules in carriers of any other relevant combination of genotypes at those loci. It was unexpected to see the highest levels of MMP-9 in carriers of the two-locus genotype -2518 *MCP-1 GG* -1607 *MMP-1 2G/2G*. We thought that preceding molecular events involving increased production of MCP-1 and MMP-1 levels might explain why these TB cases expressed the highest levels of MMP-9. We first tested whether endogenous MCP-1 and MMP-1 were involved in the induction of MMP-9 using CCR2 inhibiting compound RS504393 and MMP-1 inhibiting 4-Aminobenzoyl-Gly-Pro-D-Leu-D-Ala hydroxamic peptide. We clearly established *in vitro* that the MCP-1/MMP-1 loop drives the expression of MMP-9 to its highest levels in THP-1 cells activated by sonicated H37Rv *M. tuberculosis*. Moreover, addition of exogenous human (h)MMP-1 to THP-1 cells activated by sonicated H37Rv *M. tuberculosis* potentiated significantly the production of MMP-9. Hence, these *in vitro* data may explain why we observed the highest levels of MMP-9 in carriers of the two-locus genotype -2518 *MCP-1 GG* -1607 *MMP-1 2G/2G*. Given these observations, we concluded that it is very likely that the MCP-1/MMP-1/MMP-9 pathway is driving an intense inflammatory response to infection in lung tissues of patients carrying that susceptibility two-locus genotype. Notable, MMP-9 not only helps in recruiting macrophages to the inflammatory foci ([@R27]), but can also degrade collagen byproducts of MMP-1-digested fibrilar collagen ([@R41]).

Since it is known that MMP-1 cleaves the PAR-1 N-terminal exodomain to generate a SFLLRN-containing motif that activates the PAR-1 signaling pathway ([@R33]), we investigated whether this pathway may operate in TB. We observed by IHC that alveolar macrophages in normal lungs constitutively express PAR-1 while in few macrophages express PAR-1 in TB cases suffering from severe lung disease. Nevertheless, we concluded that lung macrophages express PAR-1 in healthy and to a lesser extend in disease lung parenchyma. Our FACS analysis experiments suggested that MMP-1 activates PAR-1 in monocytic cells exposed to *M. tuberculosis* antigens. We first established that as a result of exposure to *M. tuberculosis* antigens, PAR-1 expressed in CD14-positive/CD16-negative THP-1 cells was significantly down-regulated, which may indicate that an specific ligand was activating, and subsequently inducing the recycle of this receptor. Addition of MMP-1 inhibitor 4-Aminobenzoyl-Gly-Pro-D-Leu-D-Ala hydroxamic peptide to the cultures significantly neutralized *M. tuberculosis* antigen-induced down-regulation of PAR-1 expression in these cells, indicating that MMP-1 was one of the molecules activating PAR-1. Furthermore, in agreement with our observation that MCP-1 potentiates MMP-1 secretion by THP-1 cells exposed to sonicated H37Rv *M. tuberculosis*, we also observed that the addition of CCR2 inhibitor RS504393 prevents the activation, and consequently, the down-regulation of PAR-1 expression by CD14-positive/CD16-negative THP-1 cells. Since THP-1 cells did not express thrombin under those conditions, we concluded that MMP-1 might be one of the proteases activating PAR-1, and thereby inducing the recycling of activated PAR-1 in our *in vitro* system.

We also conducted studies to directly determine the possible role of PAR-1 activation by MMP-1 in TB, adding exogenous human MMP-1 to THP-1 cells activated with sonicated *M. tuberculosis* H37Rv. These experiments corroborated a link between the MCP-1/MMP-1 up-regulation of MMP-9 with activation of PAR-1 in monocytes/macrophages. Addition of PAR-1 inhibitor SCH79797 at nanomolar concentration to THP-1 cells stimulated with sonicated *M. tuberculosis* H37Rv or THP-1 cells infected *in vitro* with *M. tuberculosis* H37Rv significantly down-regulated MCP-1, MMP-1, and MMP-9 expression, while the TIMPs remained poorly expressed. Likewise, addition of this PAR-1 inhibitor, at nanomolar concentration, to cultures of *M. tuberculosis*-stimulated THP-1 cells that proceeded in the presence of exogenous hMMP-1 resulted in inhibition of MCP-1, MMP-1, and MMP-9 expression. Interestingly, this PAR-1 inhibitor down-regulated the expression of CCR2 in infected cells, which may contribute to decrease the effect of excessive MCP-1 production.

The similarities between the results from the reanalysis of data from a genome-wide comparison of gene expression in human granulomatous lesions mentioned above ([@R40]), and the data we have obtained from *M. tuberculosis* infections of THP-1 cells, provides physiological relevance to our *in vitro* observations. It will be interesting to study the effects of the compound or peptide inhibitors we have tested, alone or in combinations, on primary human CD14+ CD16− and CD14+ CD16+ macrophages. Likewise, since we did not attain an efficient transient transformation of a significant proportion of THP-1 cells with specific siRNA, it will be important to generate, for future experiments, stable THP-1 transfectants expressing specific siRNAs.

It is extremely interesting that a functional SNP in the promoter region of *leukotriene A4 hydrolase* (*LTA4H)*, the genotype *TT*, drives increased expression of the *LTA4H* gene and decreased survival of TB patients affected with meningitis ([@R3]). The significance of this finding is that LTA4H is a key enzyme in the generation of leukotriene B4 (LTB4), and that an excess of LTB4 results in excessive production of TNFα and subsequent macrophage necrosis ([@R3]). Since the PAR-1 and LTB4 receptors BLT1 and BLT2 are G-protein-coupled receptors (GPCR) expressed in macrophages and it is known that crosstalk exist between GPCRs ([@R3], [@R42]), it will be interesting to investigate whether CCR2 or PAR-1 and LTB4 receptors crosstalk, and if they do crosstalk, whether they crosstalk in an agonistic or antagonistic fashion. Notably, we do not rule out that the -2518 *MCP-1* genotype *GG* or the -1607 *MMP-1* genotype *2G/2G* may drive, alone or in interaction with other genes, the expression of severe TB disease in other populations. In fact, there is evidence that the -2518 *MCP-1* genotype *GG* influences the expression of meningitis in Chinese TB patients of pediatric age ([@R43]).

We know at least that PAR-1 inhibition do not increase *M. tuberculosis* proliferation in THP-1 cells, as we assessed this experimentally. However, more in-depth studies are needed to determine whether disease modification by inhibitors of the MCP-1/MMP-1/PAR-1 pathway may serve as an adjuvant of current chemotherapy to avoid the expression of a severe disease and permanent lung damage in human carriers of the two-locus genotype -2518 *MCP-1 GG* -1607 *MMP-1 2G/2G*. Targeting the MCP-1/MMP-1/PAR-1 pathway to decrease active tissue damage may also help to shorten the time needed to achieve sputum sterilization by chemotherapy in these patients.

All together, our results uncovered a new concept that the two-locus genotype -2518 *MCP-1 GG* -1607 *MMP-1 2G/2G* increases the chance of developing severe pulmonary TB. We are also reporting that MMP-1 can operate a positive feed-back induction of MCP-1 and MMP-9 through PAR-1 activation, and that inhibition of PAR-1 activation down-regulates the MCP-1/MMP-1/MMP-9 pathway in monocytic cells exposed to sonicated H37Rv or infected with H37Rv *M. tuberculosis* strain. That in fact TNFα up-regulation in response to infection is not modified in THP-1 cells by treatment with SCH79797 PAR-1 inhibitor is encouraging since this is a factor critically involve in the development of cellular immune response against *M. tuberculosis* infection ([@R37]). Studies in animal models are needed to confirm *in vivo* these molecular mechanisms and to confirm that the PAR-1 inhibitor SCH79797 constitutes a promising candidate for the treatment of MCP-1/MMP-1 mediated tissue damage in TB. Thus, our finding that MMP-1, through PAR-1 activation, is driving a hyper-inflammatory in response to infection highlights key molecular events for the development of new clinical interventions to attenuate tissue damage.

PATIENTS, MATERIALS AND METHODS {#S12}
===============================

Ethics Statement {#S13}
----------------

All subjects provided informed consent, under protocols approved by the Institutional Review Boards of The Methodist Hospital Research Institute (TMHRI) in Houston (Texas, USA), and the Peruvian Ministry of Health.

Recruitment Base {#S14}
----------------

People from Peru are of Hispanic ancestry whose genetic composition consists mainly of an admixture of Amerindians and Spaniards. People with this genetic composition are the main ethnic group in most Latin-American countries and of Hispanics living in the United States (US). Peru is a moderate-to-high tuberculosis-burdened country ([@R44]). The TB Incidence in 2010 was 118 per 100,000 person-years and the prevalence of TB was 187 per 100,000 person-years ([@R44]). The existence of government-run, community-based programs designed to detect new TB cases in Peru facilitate identification of well-characterized study subjects ([@R45]). We recruited our cases using a sentinel surveillance network comprised of primary (community) health centers under the jurisdiction of two National Hospitals (serving a total population of 10 million individuals) in Lima Province, the Hospital Hipolito Unanue and the Hospital Maria Auxiliadora. All TB cases were residents of communities sharing similar TB incidence, socioeconomic status and life styles, and very likely similar *M. tuberculosis* strains. Most of the individuals suffering from TB in Peru are of low socioeconomic status ([@R44], [@R45]).

Inclusion and exclusion criteria {#S15}
--------------------------------

We conducted a case-case study of homogeneous populations of Peruvian Mestizo ancestry. From July 2009 to July 2011, we recruited 224 TB cases meeting our inclusion/exclusion criteria. TB cases were unrelated to the third generation as determined by a questionnaire, aged \> 18 to ≤ 50 years old. They were of Peruvian ethnicity to the third generation, increasing the likelihood that this population is ethnically homogeneous. Patients were not HIV-seropositive, and/or did not have co-morbidities affecting immunity, including autoimmunity, cancer, organ transplantation, primary immunodeficiency, were not on therapy with immunosuppressive drugs (such as corticosteroids), and did not suffer from endocrine disorders, or chronic cardiopulmonary, hepatic, or renal disease. Patients did not suffer from alcoholism and were not illegal drug users. Body mass index (BMI) was used as an indicator of malnourishment in adults ([@R46], [@R47]). The BMI was determined based on weight and height measured by a nurse, as we did before ([@R1], [@R2]). We selected TB patients meeting the following criteria: 1) Completeness of demographic and clinical data; 2) all TB cases were new with a disease of no more than 3 months of duration. We excluded cases of recurrent or re-infected TB. Recruitment of new cases avoids confounding of data by unmeasured (unknown) factors that increase the chance of recurrent or re-infected TB; 3) Patients who developed TB disease within a period of two years following the most recent close exposure to an index case; 4) TB patients identified at the local (community) TB control center to avoid selection bias of choosing a disproportionate number of TB cases with a severe disease presentation that needed specialized clinical interventions at secondary or tertiary hospitals. Physicians at the local TB control center identified all cases; 5) Patients with positive adherence to treatment. Patients had: (i) signs and symptoms of active TB; (ii) a full-size posteroanterior chest X-ray suggestive of active pulmonary TB; (iii) disease confirmed by at least one of three positive sputum smear test; (iv) monthly sputum smear tests to follow up sputum smear test conversion from positive to negative. New TB patients in Peru received a four-drug standardized treatment consisting of 300 mg of Rifampicin + 300 mg of Isoniazid + 1500 mg of Pyrazinamide + 1200 mg of Ethambutol daily for 2 months, followed by 300 mg of Rifampicin + 300 mg of Isoniazid twice a week for 2 months ([@R45]).

The severity score {#S16}
------------------

We defined disease duration as the length of time since the first symptom was noticed by the patient to the time of sampling. The total score is the sum of a score based on the assessment of clinical signs and symptoms plus a score based on the assessment of posteroanterior full-size chest X-rays (total from the independent assessment of the two lungs; [Table 2](#T2){ref-type="table"}). BMI in adults was assessed according to the World Health Organization (WHO) chart. Anemia was assessed by levels of hemoglobin according to gender and laboratory standards. Fever was assessed by axillary temperature ≥ 37.0 °C measured by an electronic thermometer in a closed axillary fold. Any abnormal sign at lung auscultation provided by a physician was used to assign a score to this item. The extent of lung lesions and type of lesions were evaluated for each lung independently. Clinical presentations (e.g. miliary and meningitis TB) were also scored when present.

Sample size calculation of the case-case study {#S17}
----------------------------------------------

Based on preliminary data from the analysis of 108 TB cases, a logistic regression of a binary response variable (Y) on an independent variable with 4 levels, adjusted for an additional 2 independent variables with a sample size of 206 observations will achieve 90% power at a 0.01 significance level to detect a change in probability (Y=1) from the baseline value of 0.05 to 0.24 in the comparison of the strata of interest with other stratum. This change corresponds to an odds ratio of 6 ([@R48]).

Blood Samples and SNP Analysis {#S18}
------------------------------

Genomic DNA was isolated from blood cell pellets using DNA extraction kits (Qiagen, Valencia, CA). We genotyped the *-2518A\>G* SNP in *MCP-1* (rs1024611), the -*1607_1608insG* variant in *MMP-1* (rs1799750), and 42 genomic control SNPs ([@R2]). The rs1024611 and rs1799750 SNPs were genotyped in duplicate using the tetra-primer ARMS PCR technique ([@R2]). We did not find discrepancies in the typing results for *MCP-1* and *MMP-1*. We will make primer sequences available and procedures available upon request. To confirm our results for the *MCP-1* and *MMP-1* gene analysis, we sequenced 10 randomly selected samples. The 42 SNPs used as genomic controls in Peruvians were genotyped using an Illumina platform ([@R2]). We obtained λ values of admixture as we did before ([@R1], [@R2]). Given that Africans are the founders of all human races and that the -2518 *MCP-1* allele *A* and the -1607 *MMP-1* allele *1G* are the most frequent in this population ([@R2]), we used them as reference alleles.

We randomly selected 30 TB cases from each stratum by genotypes and 20 normal subjects to assess the levels of MCP-1 in serum, and MMP-1 and MMP-9 in plasma. We used serum to assess MCP-1 levels because we figured up that the data obtained from serum was more reproducible compared to that of plasma. Serum was tested at a 1:4 dilution and plasma for MMP-1 in 1:4 and for MMP-9 in 1:8 dilutions. MCP-1 levels were measured by ELISA (BD Biosciences). MMP-1 and MMP-9 were measured using Fluorokine E, Human Active MMP-1 or Fluorokine E, and Human Active MMP-9 kits (R&D Systems). These Fluorokine assays measured the amount of cleaved collagen peptide by monitoring fluorescence. These assays are functional assays since the antibodies capture only free MMP-1 and MMP-9. The levels of MCP-1, MMP-1, and MMP-9 were obtained using a Multi-mode Microplate Reader Synergy 2 (BioTek Instruments Inc., Winooski, VT).

IHC analysis of lung tissues {#S19}
----------------------------

For IHC, lung tissue samples from the six TB cases that underwent surgery were fixed in paraformaldehyde and embedded in paraffin. Lung samples from normal individuals were provided by the Department of Pathology and Genomic Medicine at the Methodist Hospital. For IHC, we used heat-induced epitope retrieval in citrate buffer (Thermo/Fisher Scientific Inc., Waltham, MA), rabbit anti-human CCL2/MCP-1 polyclonal antibody LS-C112304 (LifeSpan Bioscience, Inc), rabbit anti-human MMP-1/Collagenase-1 Ab-6 (Thermo/Fisher Scientific, Inc), rabbit anti-human MMP-9 ab13458 (Millipore), rabbit anti-human PAR-1 ab13398 (abcam), mouse anti-human CD68 KP1 (abcam), and the MultiVision Polymer Detection System/anti-mouse-HRP (red) + anti-rabbit-AP (blue) detection system (Lab Vision Products, Thermo Scientific). We immunostained 5-μm thick sections in duplicate for each case. Negative controls were sections incubated with irrelevant normal Rabbit IgG (KPL Inc., Gaithersburg, ME) or irrelevant normal mouse IgG antibody (R&D Systems). We used 1X Automation buffer pH 7.5 (Biomeda Inc., Albuquerque, NM) in all wash steps. SuperMount permanent aqueous mounting media (BioGenex, San Ramon, CA) was used for mounting immunostained tissue sections. Immunostained tissue sections were assessed at 200X and 100X total magnification and 0.8 numerical aperture of the objective lenses. Image acquisition was performed using a computerized analysis system comprising: a BX41 microscope with a U-TVIX-2 and a U-CMAD3 tube and adapter attached for on-screen viewing, a C3040 4.1 megapixel digital camera, and Magnafire-SP software (Olympus America Inc.).

Culture Conditions and RT-PCR Assay {#S20}
-----------------------------------

For the assessment of *MCP-1, MMP-1, MMP-9, TIMP-1, -2, -3, and -4* expression, we used the 7500 Fast Real-Time PCR System and assay-on-demand primers for *MCP-1* (ID Hs00234140)*, MMP-1* (ID Hs00233958), *MMP-9* (ID Hs00234579), *TIMP-1* (ID Hs00171558), *TIMP-2* (ID Hs01091319), *TIMP-3* (ID Hs00227214), *TIMP-4* (ID Hs00162784), and the house-keeping gene *PDHB* (*Pyruvate dehydrogenase beta*, ID Hs00168650) (Applied Biosystems). To calculate the relative quantity (RQ) of mRNA expression, we used the 2 ^−ΔΔCT^ method implemented in the software (Applied Biosystems). The data are presented as the fold change in gene expression normalized to the endogenous reference gene PDHB and relative to the untreated controls (RQ values). THP-1 cells (1×10^6^ cells/ml) were stimulated with the indicated amounts of H37Rv *M. tuberculosis* lysate obtained after sonication (sonicated H37Rv *M. tuberculosis*) as described previously (Ganachari et al. 2010), or the indicated amounts of CCR2 RS504393 (Tocris), MMP-1 4-Aminobenzoyl-Gly-ProD-Leu-D-Ala hydroxamic peptide (SIGMA), PAR-1 SCH79797 (Tocris) inhibitors, and human purified MMP-1 (hMMP-1) activated with p-aminophenylmercuric acetate (EMD Chemicals). THP-1 cells were cultured for 24 hr in incomplete RPMI as indicated in the figure legends. Cells were then harvested and total RNA was extracted using TRIzol (Invitrogen). Complementary DNA (cDNA) was obtained from 3 μg of total RNA using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Approximately 100 ng cDNA was used to determine the expression levels of the housekeeping gene *PDHB* and *MCP-1, MMP-1, MMP-9, and TIMPs*.

Three-color FACS analysis {#S21}
-------------------------

THP-1 cells cultured as described above were harvested and washed twice in cold incomplete RPMI, then re-suspended in 100 μl of cold incomplete RPMI containing 10 μg/ml of human IgG (SIGMA), and incubated on ice for 15 min. Cells were washed once in PBS + 10% BSA (SIGMA) and re-suspended at 5 × 10^5^ cells/100 μl of this buffer. FITC-anti-human CD14 mouse monoclonal antibody 61D3 (Santa Cruz Biotechnology, Inc), PerCP-Cy5.5 anti-human CD16 mouse monoclonal antibody DJ130c (Santa Cruz Biotechnology, Inc), and APC anti-human F2R/PAR-1 mouse monoclonal antibody ATAP2 or appropriately labeled isotype controls were added to the cells and incubated for 30 min on ice. Cells were then washed thoroughly and re-suspended in cold PBS. Acquisition was done using the BD LSR II instrument and software. We acquired 10,000 to 100,000 events as indicated in the figure legends. The analysis of data was done using the FlowJo 7.6.4 software. CD14-positive/CD16-negative cells were gated for the analysis of F2R/PAR-1 expression.

Infections of THP-1 cells and gene expression microarrays {#S22}
---------------------------------------------------------

We used the *M. tuberculosis* H37Rv (ATCC) grown in Middlebrook 7H9 broth supplemented with ADC enrichment (Difco Laboratories), 2% glucose, and 1% glycerol. Cultures proceeded at 37°C and slow constant shaking to mid-log growth phase (7 to 10 days). The Bacteria were quantified using McFarland equivalence turbidity standards (Thermo Scientific). Fresh cultures of 10^6^ to 10^8^ bacilli/ml bacteria were immediately used for infections. To determine *M. tuberculosis* CFU cell pellets were obtained by centrifugation at 1,500 rpm and the cell pellets were lysed in 0.1% Triton X-100 (Sigma) before preparation of plating dilutions. We counted colony forming units (CFU)/ml by serial titration of cultures 1:10, 1:100, and 1:1,000 in 7H9 plated on 7H11 agar plates, and left in culture for 3 weeks at 37°C.

THP-1 cells were infected with *M. tuberculosis* bacilli at a multiplicity of infection (MOI) of 5 bacteria per cell in complete RPMI (10% FBS) without antibiotics. We used this culture media throughout the experiments, unless indicated. THP-1 cells and *M. tuberculosis* bacilli were incubated for 6 hours at 37°C in 5% CO~2~, then washed 3 times in incomplete RPMI and plated at 1 million cells/0.5 ml of culture media in 48-well plates. We then added the PAR-1 inhibitor SCH79797 (Tocris) at a final culture concentration of 50 nM. The PAR-1 inhibitor was previously diluted in DMSO at a 5 μM working concentration to dispense a 5 μl volume per well and to produce the desired concentration of PAR-1 inhibitor and a final culture concentration of 0.01% DMSO. Control cultures of infected cells contained 0.01% DMSO alone. Then the cultures proceed for additional 18 hours when we proceed to harvest the THP-1 cells for isolation of RNA or for CFU determinations, and to harvest the culture supernatants for ELISA tests. We did not induce differentiation of THP-1 cells previous to infection since exposure of THP-1 cells to *M. tuberculosis* (or *M. tuberculosis*-sonicate) induces differentiation of these cells into macrophage-like adherent cells.

Total RNA from these samples was extracted using Trizol followed by total RNA purification using Qiagen Kit as per manufacturer's instructions. We assessed the quality of RNA using Agilent RNA 6000 Nano Kit. Gene expression profiling was performed using the Illumina HumanHT-12v4 BeadChip (Illumina Inc.). Two hundred nanograms of total RNA were labeled using a TotalPrepRNA Amplification Kit (Applied Biosystems) to obtain biotinylated-cRNA. We quantified and ascertained the fragment size using the Agilent RNA 6000 Nano Kit. We loaded the beadchip's arrays with 750 ng of biotinylated-cRNA and left they hybridized overnight. We then washed and scanned the BeadChip arrays according to the manufacturer's instructions. The chips were scanned using the Illumina BeadArray Reader.

Statistical analysis {#S23}
--------------------

Statistical analysis was done with Intercoiled STATA10 software (Stata Corporation). Chi^2^ test or student t-test was used to assess differences between categorical or continuous variables, respectively. The severity of disease was first established by expert clinicians in the field. Each TB case had a clinical diagnosis of disease severity as: non-severe or severe disease. Once the severity scores were obtained, we classified the cases according to whether they had severity score values above or ≤ the median. We used the Kappa statistic and a modified Rietveld and van Houd scale ([@R49]), to evaluate agreement between: (i) an expert clinician assessment of the cases, and (ii) the severity of disease classification obtained by another clinician using our clinical charts and [table 2](#T2){ref-type="table"} (severity scores). According to this scale, the interpretation of Kappa coefficients is as follows: \<0 = Less than chance agreement, 0.01--0.2 = Slight agreement, 0.21--0.40 = Fair agreement, 0.41--0.60 = Moderate agreement, 0.61--0.8 = Substantial agreement, 0.81--0.99 = Almost perfect agreement, 1 = perfect agreement ([@R49]). We treated the severity scores as a dependent binary random variable \[0 = non-severe score (score ≤ 44); 1 = severe disease (score \> 44); [Table 3](#T3){ref-type="table"}\], and assessed the contribution on severity of disease of each locus and the two-locus genotypes, adjusting for age and gender using logistic regression analysis. We performed Pearson Goodness-of-Fit *x*^2^ tests to determine whether the observed models differed from the predicted. We used the non-parametric Kruskal-Wallis test, followed by the Bonferroni least significant difference (LSD) test for multiple comparisons to analyze differences in the mean severity score stratified according to genotypes. Spearman's test was used to evaluate correlations. We used multiple 2 × 2 tables, with genotype arranged in an ordinal scale, and Chi^2^ Mantel-Haenszel statistics to test for genotypes associations with delayed (\> 3 months) sputum smear test conversion primarily to obtain valid estimates for association for each stratum, and to assess dose effects and homogeneity of the odd ratios (OR) across strata. To test for homogeneity of OR, we used the Breslow and Day's test provided in the SATA10 output. One-way ANOVA followed by a Bonferroni LSD test was used to evaluate results from the assessment of serum/plasma levels of MCP-1, MMP-1, and MMP9, and to evaluate results from *in vitro* experiments designed to test contributions of MCP-1/CCR2, MMP-1, and PAR-1 pathways in models of *M. tuberculosis*-induced expression of inflammatory factors by THP-1 cells.

We subtracted the background to the raw data obtained from the Illumina platform and proceed to normalized data using quantile normalization ([@R50]). We excluded probes showing detection p-values less than 0.05. All the statistical analyses of the expression data were conducted using the GenomeStudio package (Illumina). The p-values were obtained using false discovery rate (FDR) for multiple testing adjustments ([@R51]). Given that the scores obtained for each gene were a function of the p-values, we calculated the log2 of the average-signal's ratios (log-ratios) to assess the magnitude and orientation (up- or down-regulation) of the gene regulation. We declare significant change in expression when FDR-adjusted p-values were ≤ 0.05 and the log2-ratios ≥ 1.5, regardless of the orientation.

Supplementary Material {#S24}
======================

###### Figure S1. PAR-1 is expressed in some alveolar macrophages in lung tissues from severe TB cases

We used double IHC analysis of PAR-1(blue) and CD68 (red) in paraffin-embedded diseased lung. Representative images from three of the six TB cases that underwent surgery to remove damaged tissue are shown. In section A we show the negative control (irrelevant antibodies isotype control). Images were acquired at 100X total magnification.

###### Figure S2

A model of MCP-1/MMP-1/PAR-1 pathway-caused tissue damage in TB cases carrying the two-locus genotype -2518 *MCP-1 GG* -1607 *MMP-1 2G/2G*. **PHASE I:** After exposure to *M. tuberculosis,* ganuloma macrophages express MCP-1 and MMP-1. Persons carrying the two-locus genotype -2518 *MCP-1 GG* -1607 *MMP-1 2G/2G* produce excessive amounts of these factors. **PHASE II:** MCP-1 activates CCR2 receptors and potentiates *M. tuberculosis*-induced MMP-1 production. MMP-1 targets fibrilar collagen in the granulomatous matrix, resulting in matrix degradation. Persons carrying the two-locus genotype -2518 *MCP-1 GG* -1607 *MMP-1 2G/2G* experience matrix degradation, an event that, in normal individuals, is not as intense and is part of the normal healing process. **PHASE III:** The excess of MMP-1 intensifies the granulomatous matrix degradation and activates the PAR-1 receptors. **PHASE IV:** Activation of PAR-1 increases MCP-1, MMP-1, and induces secretion of MMP-9. MMP-9 may contribute to MCP-1-mediated monocyte recruitment and further degradation of the granulomatous matrix. PAR-1 activation is a key event in the amplification of the inflammatory process (a hyper-inflammatory state) and in the induction of extensive tissue damage.
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![TB patients carrying the two-locus genotype -2518 *MCP-1 GG* -1607 *MMP-1 2G/2G* express MCP-1, MMP-1, and MMP9\
We used double IHC analysis of MCP-1 or MMP-1 or MMP-9 and CD68 in paraffin-embedded diseased lung from six TB patients who underwent surgery to remove damaged tissue. We are showing representative data. A: negative control (irrelevant antibodies isotype control); B: MCP-1 (blue) and CD68 (red); C: MMP-1 (blue) and CD68 (light red); D: MMP-9 (blue) and CD68 (light red). Images were acquired at 200X total magnification. IHC analysis shows granulomas with CD68-positive cells (macrophages) expressing copious amounts of MCP-1, MMP-1, and MMP-9.](nihms398267f1){#F1}

![TB patients carrying the two-locus genotype -2518 *MCP-1 GG* -1607 *MMP-1 2G/2G* have the highest serum levels of MCP-1 and the highest plasma levels of MMP-1 and MMP9\
Values are shown as medians (horizontal lines), the 25th and 75th percentiles (boxes), and ranges (whiskers). Legends in the x-axis mean: 1 = two-locus genotype *A/- 1G/-;* 2 = two-locus genotype *A/- 2G/2G;* 3 = two-locus genotype *GG 1G/-;* 4 = two-locus genotype *GG 2G/2G*). Section A: Distribution of serum MCP-1 values for tuberculosis patients stratified according to the relevant two-locus genotypes. We observed a significant difference in the serum levels of MCP-1 across genotypes (ANOVA F = 16.31; p = 0.0001). Section B: Distribution of plasma MMP-1 values for tuberculosis patients stratified according to the relevant two-locus genotypes. We observed a significant difference in the plasma levels of MMP-1 across genotypes (ANOVA F = 5.76; p = 0.001). Section C: Distribution of plasma MMP-9 values for tuberculosis patients stratified according to the relevant two-locus genotypes. We observed a significant difference in the plasma levels of MMP-9 across genotypes (ANOVA F = 8.25; p = 0.0001). Comparison of means and standard deviations by genotypes are shown at the right of the whiskers and box figures. The p-values are based on the Bonferroni least significant difference test.](nihms398267f2){#F2}

![CCR2 RS504393 and MMP-1 4-Aminobenzoyl-Gly-Pro-D-Leu-D-Ala hydroxamic peptide inhibitors modulate the expression of MCP-1, MMP-1, and MMP-9 and, to a lesser extent the expression of TIMPs inTHP-1 monocytic cells stimulated by sonicated H37Rv *M. tuberculosis*\
We measured the relative changes in *MCP-1, MMP-1*, *MMP-9,* and *TIMP* gene expression by real-time PCR. Data are presented as the fold change in gene expression normalized to the endogenous reference gene *PDHB* and relative to untreated controls. **Panel 1**, the effect of 10 μM concentration of CCR2 RS504393 inhibiting compound was assessed following 24 hr *in vitro* stimulation of THP-1 cells with 5 μg/ml sonicated H37Rv *M. tuberculosis*. Cultures proceeded in 500 μl serum-free RPMI. CCR2 RS504393 inhibiting compound was diluted with DMSO and dispensed in 5 μl volume to produce a final culture concentration of 0.01% DMSO. We also added 5 μl of DMSO to control cultures. The results presented are from six independent experiments showing the mean and standard deviations. We consistently observed significant differences in the mean values across variables (Kruskal-Wallis p \< 0.01) when testing MCP-1, MMP-1 and MMP-9. We show corrected p-values obtained from student t-tests. Notably, levels of specific mRNAs from non-stimulated cells were not significantly different than those obtained from cultures that proceeded with the CCR2 inhibitor alone. **Panel 2**, the effect of 1 μM concentration of MMP-1 inhibitor 4-Aminobenzoyl-Gly-Pro-D-Leu-D-Ala hydroxamic peptide was assessed following 24 hr *in vitro* stimulation of THP-1 cells with 5 μg/ml sonicated H37Rv *M. tuberculosis*. Cultures proceeded in 500 μl serum-free RPMI. 4-Aminobenzoyl-Gly-Pro-D-Leu-D-Ala hydroxamic peptide was diluted in incomplete RPMI. The results presented are from six independent experiments showing the mean and standard deviations from the mean. We consistently observed significant differences in the mean values across variables (Kruskal-Wallis p \< 0.01) when testing MCP-1, MMP-1 and MMP-9. We show corrected p-values obtained from student t-tests. Of note, levels of specific mRNAs from non-stimulated cells were not significantly different from those obtained from cultures that proceeded with the 4-Aminobenzoyl-Gly-Pro-D-Leu-D-Ala hydroxamic peptide inhibitor alone. The inhibitors' concentrations were selected from dose response-experiments.](nihms398267f3){#F3}

###### PAR-1 is expressed in alveolar macrophages from normal lungs, while only few macrophages expressed PAR-1 in diseased lung tissues from severe TB cases

We used double IHC analysis of PAR-1 and CD68 in paraffin-embedded normal (Panel 1) and diseased lung (Panel 2). Sections B, C, and D show three different normal persons (Panel 1). One representative image from three of the six TB cases that underwent surgery to remove damaged tissue is shown in Panel 2. In each panel, Section A shows the negative control (irrelevant antibodies isotype control). Sections B, C, and D show PAR-1 (blue) and CD68 (dark red) macrophages. Images were acquired at 200X total magnification.

![](nihms398267f4a)

![](nihms398267f4b)

![Down-regulation of PAR-1 expression by exposure of THP-1 cells to sonicated H37Rv *M. tuberculosis* and counter effect of MMP-1 and CCR-2 inhibitor\
We used three-color FACS analysis for these experiments. Exposure of quiescent THP-1 cells to sonicated H37Rv *M. tuberculosis* for 24 hr induced the differentiation of these cells into CD14-positive/CD16-negative cells. In Panels 1 and 2, Section A shows a low proportion of CD14-positive/CD16-negative cells in quiescent THP-1 cells; Section B shows an increment in the proportion of CD14-positive/CD16-negative THP-1 cells in response to sonicated H37RV *M. tuberculosis* exposure.; Section C shows minimal (non-significant) variation in this response to sonicated H37Rv *M. tuberculosis* exposure in the presence of the MMP-1 inhibitor (Panel 1) or CCR2 inhibitor (Panel 2). In Sections D, E, and F of Panel 1, we show that the presence of MMP-1 inhibitor 4-Aminobenzoyl-Gly-Pro-D-Leu-D-Ala hydroxamic peptide prevents the down-regulation of PAR-1 expression by THP-1 cells exposed to sonicated H37Rv *M. tuberculosis* exposure. In Sections D, E, and F of Panel 2, we show that the presence of CCR2 inhibitor RS504393 also prevents the down-regulation of PAR-1 expression by THP-1 cells exposed to sonicated H37Rv *M. tuberculosis* exposure. We acquired 100,000 events for experiments in Panel 1, while we acquired 10,000 events for experiments in Panel 2, according to the number of live cells gathered in each experiment. Of note, the MMP-1 inhibitor was dissolved in incomplete RPMI while the CCR2 inhibitor was dissolved in DMSO to obtain a DMSO final culture concentration of 0.01%. Three experiments were done for the assessment of each inhibitor.](nihms398267f5){#F5}

![PAR-1 inhibitor SCH79797 regulates the expression of MCP-1, MMP-1, and MMP-9 in THP-1 monocytic cells stimulated by sonicated H37Rv *M. tuberculosis* and THP-1 cells stimulated by sonicated H37Rv *M. tuberculosis* in the presence of exogenous purified human MMP-1\
**Panel 1,** we measured the relative changes in *MCP-1, MMP-1*, *MMP-9,* and *TIMP* gene expression by real-time PCR. Data are presented as the fold change in gene expression normalized to the endogenous reference gene *PDHB* and relative to untreated controls. The effect of 50 nM concentration of SCH79797 PAR-1 inhibiting compound was assessed following 24 hr *in vitro* stimulation of THP-1 cells with 5 μg/ml sonicated H37Rv *M. tuberculosis*. Cultures proceeded in 500 μl incomplete RPMI. PAR-1 SCH79797 inhibiting compound was diluted with DMSO and dispensed in 5 μl volume to produce a final culture concentration of 0.01% DMSO. We also added 5 μl of DMSO to control cultures. The results presented are from six independent experiments showing the mean and standard deviations. We consistently observed significant differences in the mean values across variables (Kruskal-Wallis p \< 0.001) when testing MCP-1, MMP-1 and MMP-9. We show corrected p-values obtained from student t-tests. Of note, levels of specific mRNAs from non-stimulated cells were not significantly different from those obtained from cultures that proceeded with the PAR-1 inhibitor alone. **Panel 2**, the effect of 1 nM exogenous human purified MMP-1 on THP-1 cells exposed to 5 μg/ml sonicated H37Rv *M. tuberculosis* was assessed. We also assessed the effect of 1 nM exogenous human purified MMP-1 on THP-1 cells exposed to 5 μg/ml sonicated H37Rv *M. tuberculosis* in the presence or absence of 50 nM concentration of SCH79797 PAR-1 inhibiting compound. We measured the relative changes in *MCP-1, MMP-1*, and *MMP-9* gene expression by real-time PCR as explained above. Cultures proceeded in 500 μl of incomplete RPMI. The results presented are from three independent experiments showing the mean and standard deviations. We consistently observed significant differences in the mean values across variables (Kruskal-Wallis p \< 0.001) when testing MCP-1, MMP-1 and MMP-9. We show corrected p-values obtained from student t-tests. The inhibitor's concentration was selected from dose response-experiments.](nihms398267f6){#F6}

###### 

TB cases -- characteristics

  two-locus genotypes                               Group 1: *A/- 1G/-*   Group 2: *A/- 2G/2G*   Group 3: *GG 1G/-*   Group 4: *GG 2G/2G*   Statistics
  ------------------------------------------------- --------------------- ---------------------- -------------------- --------------------- -----------------------------------------------
  **TB cases per genotype n (%) (total n = 224)**   51 (23%)              59 (26%)               43 (19%)             71 (32%)              n.s.[\*](#TFN9){ref-type="table-fn"}
  **Mean age ± SD**                                 33.9 ± 10.8           31.63 ± 10.9           28.95 ± 9.3          29.7 ± 10.06          n.s.[\*](#TFN9){ref-type="table-fn"}
  **Women n (%)**                                   23 (45%)              27 (46%                20 (47%)             31 (44%)              n.s.[\*](#TFN9){ref-type="table-fn"}
  **Duration of disease (days)**                    63 ± 20               64 ± 20                65 ± 22              64 ± 24               n.s.[\*](#TFN9){ref-type="table-fn"}
  **BMI ≤ the median n (%) Median = 21.21**         19 (37.3)             26 (44.06)             22 (51.2)            45 (63.4)             p = 0.026[\*\*](#TFN10){ref-type="table-fn"}
  **Severity score \> median n (%) Median = 44**    14 (27.5)             20 (33.9)              8 (18.6)             59 (83)               p \< 0.001[\*\*](#TFN10){ref-type="table-fn"}

Group 1 = *genotypes AA 1G/1G, AA 1G/2G, AG 1G/1G, AG 1G/2G*

Group 2 = *genotypes AA 2G/2G, AG 2G/2G*

Group 3 = *genotypes GG 1G/1G, GG 1G/2G*

Group 4 = genotypes *GG 2G/2G*

SD = standard deviation of the mean

n = number of cases

BMI = Body mass index

n.s. = not significant

One-way ANOVA was used to test for significant differences

Chi-squared test was used to test for significant differences

###### 

Severity score

  I. Clinical signs and symptoms                                      Score if present
  ------------------------------------------------------------------- ----------------------
  **Cough**                                                           10
                                                                      
  **Dyspnoea**                                                        10
                                                                      
  **Night sweats**                                                    10
                                                                      
  **Haemoptysis**                                                     
  At least one episode                                                10
  More than one episode                                               20
                                                                      
  Chest pain                                                          10
                                                                      
  **Decreased body mass index (BMI) in adults**                       
  BMI \< 25 to 18.5                                                   2
  BMI \< 18.5 to 17                                                   4
  BMI \< 17 to 16                                                     6
  BMI \< 16                                                           10
                                                                      
  **Low BMI for age percentile in children**                          
  BMI \< 50th but \> 25th percentile for age                          2
  BMI in the 25th to no more than 10th percentile                     4
  BMI in the 10th to more than 5th percentile                         6
  BMI below the 5th percentile                                        10
                                                                      
  **Anemia**                                                          10
                                                                      
  **Fever**                                                           10
                                                                      
  **Signs at lung auscultation**                                      10
                                                                      
  **Extra-thoracic involvement**                                      20
                                                                      
  **II. Chest-X-ray assessment**                                      **Score if present**
                                                                      
  **Extension of the lesion (each lung is assessed independently)**   
  No more than one third of the lung field affected                   10
  One third to no more than two third of the lung field affected      20
  Two third or more of the lung field affected                        30
                                                                      
  **Type of lesion (each lung is assessed independently)**            
  Infiltration patterns                                               10
  Pleural effusion                                                    10
  Cavitary lesion                                                     20
  Caseating pneumonia                                                 20
  Miliary tuberculosis                                                20
  Lung fibrosis                                                       20
  Intra-thoracic lymphadenopathy                                      10

###### 

Contribution of age, gender and -2518 *MCP-1* -1607 *MMP-1* two-locus genotypes in TB disease severity

  ----------------------------------------------------------------------------------------------------------
  Number of observations = 224\                                                             
  LR chi-square (5) = 68.62\                                                                
  Probability \> chi^2^ = 0.00001\                                                          
  Log likelihood = −119.87\                                                                 
  Pseudo R^2^ = 0.223                                                                       
  ---------------------------------- --------------------------- -------- -------- -------- ----------------
  **Age**                            0.998                       0.0154   − 0.10   0.921    0.969 -- 1.029

  **Gender (female)**                0.667                       0.215    − 1.26   0.209    0.355 -- 1.254

  **Group 2: *A/- 2G/2G***           1.358                       0.571    0.73     0.467    0.595 -- 3.095

  **Group 3: *GG 1G/-***             0.6                         0.306    − 1.00   0.317    0.222 -- 1.63

  **Group 4: *GG 2G/2G***            13.13                       5.941    5.69     0.0001   5.41 -- 31.88

  **Pearson Goodness-of-fit:**       Chi^2^ = 151.44; p = 0.13                              
  ----------------------------------------------------------------------------------------------------------

Genotype *A/- 1G/- = genotypes AA 1G/1G or AA 1G/2G, AG 1G/1G or AG 1G/2G*

Genotype *A/- 2G/2G = genotypes AA 2G/2G, AG 2G/2G*

Genotype *GG 1G/- = genotypes GG 1G/1G, GG 1G/2G*

Group 1 was used as reference

OR = Odds Ratio; SE = standard error; Z = Z score; 95% C.I. = 95% confidence interval

###### 

Mean score value associations with the -2518 *MCP-1* and -1607 *MMP-1* two-locus genotypes

  ----------------------------------------------------------------------------------------------------------------------------------------
  Two-locus genotypes        Cases (n)                                             Score mean ± SD   Rank sum   Bonferroni LSD
  -------------------------- ----------------------------------------------------- ----------------- ---------- --------------------------
  **Group 1: *A/- 1G/-***    51                                                    39.45 ± 11.97     4047       G1 versus G2 p = n.s.\
                                                                                                                G1 versus G3 p = n.s.\
                                                                                                                G1 versus G4 p \< 0.0001

  **Group 2: *A/- 2G/2G***   59                                                    43.96 ± 12.1      6004.5     G2 versus G3 p = n.s.\
                                                                                                                G2 versus G4 p \< 0.0001

  **Group 3: *GG 1G/-***     43                                                    39.81 ± 15.21     3439       G3 versus G4 p \< 0.0001

  **Group 4: *GG 2G/2G***    71                                                    61.58 ± 17.3      11709.5    

  **Kruskal-Wallis test**    Chi-squared with ties = 72.689, d.f. = 3, p = 0.001                                
  ----------------------------------------------------------------------------------------------------------------------------------------

Genotype *A/- 1G/- = genotypes AA 1G/1G or AA 1G/2G, AG 1G/1G or AG 1G/2G*

Genotype *A/- 2G/2G = genotypes AA 2G/2G, AG 2G/2G*

Genotype *GG 1G/- = genotypes GG 1G/1G, GG 1G/2G*

n = number of cases; n.s. = not significant

SD = standard deviation of the mean

LSD = least significant difference

G1 = group 1; G2 = group 2; G3 = group 3, G4 = group 4

d.f. = degrees of freedom

###### 

Associations of the -2518 *MCP-1* and -1607 *MMP-1* two-locus genotypes and sputum conversion at more than 3 months

  ---------------------------------------------------------------------------------------------------------------------------------
  Two-locus genotypes                  Cases n (%)                                          OR      Prob \> chi^2^   95% C.I.
  ------------------------------------ ---------------------------------------------------- ------- ---------------- --------------
  Group 1: *A/- 1G/-*                  5 (9.8)                                              1       \-               \-

  Group 2: *A/- 2G/2G*                 9 (15.3%)                                            1.4     0.57             0.44 -- 4.5

  Group 3: *GG 1G/-*                   6 (13.9%)                                            1.492   0.54             0.41 -- 5.33

  Group 4: *GG 2G/2G*                  21 (29.6%)                                           3.864   0.009            1.3 -- 11.5

  Test of homogeneity (equal odds):\   Chi^2^ = 10.41, d.f. = 3; prob \> chi^2^ = 0.0154\                            
  Score test for trend of odds:        Chi^2^ = 8.61, d.f. = 1; prob \> chi^2^ = 0.0034                              
  ---------------------------------------------------------------------------------------------------------------------------------

Genotype *A/- 1G/- = genotypes AA 1G/1G or AA 1G/2G, AG 1G/1G or AG 1G/2G*

Genotype *A/- 2G/2G = genotypes AA 2G/2G, AG 2G/2G*

Genotype *GG 1G/- = genotypes GG 1G/1G, GG 1G/2G*

n = number of cases showing sputum conversion \> 3 months

OR = Odds Ratio; 95% C.I. = 95% confidence interval, d.f. = degrees of freedom

###### 

Differentially express genes in H37Rv *M. tuberculosis* infected THP-1 cells and its regulation by PAR-1 inhibitor SCH79797

  TargetID       CYTOBAND              ProbeID       NINT AVG_Sig   NINT ARRAY_SD   YINT AVG_Sig   YINT ARRAY_SD   YINT Diff. Score   YINT Diff. P-val   Log-ratios (YINT/NINT)   YIYT AVG_Sig   YIYT ARRAY_SD   YIYT Diff. Score   YIYT Diff. P-val   Log-ratios (YIYT/YINT)
  -------------- --------------------- ------------- -------------- --------------- -------------- --------------- ------------------ ------------------ ------------------------ -------------- --------------- ------------------ ------------------ ------------------------
  **EBI3**       **19p13.3**           **2810767**   16.7           9.268           910.1          311.641         31.915             0.00064            5.8                      511.5          257.594         0                  0.99998            −0.8
  **SPP1**       **4q22.1**            **3840154**   22.1           21.323          615.2          235.702         20.707             0.0085             4.8                      112.2          102.994         **−8.322**         **0.14717**        **−2.5**
  **IL4I1**      **19q13.33**          **540670**    22.2           1.29            606.9          146.803         75.194             0                  4.8                      344.7          206.619         0                  0.99998            −0.8
  **MMP1**       **11q22.2**           **3360224**   4.2            2.889           112.9          26.33           333.614            0                  4.8                      35.3           10.905          **−15.437**        **0.02859**        **−1.7**
  **IL1B**       **2q13**              **840685**    29.5           9.647           681            106.828         333.614            0                  4.5                      401            146.768         −2.186             0.60445            −0.8
  **CCL3**       **17q12**             **6590682**   13.2           4.007           217.2          27.128          333.614            0                  4.0                      173.5          83.115          0                  0.99998            −0.3
  **CXCL10**     **4q21.1**            **6270553**   14.3           4.081           206.9          55.44           51.663             0.00001            3.8                      219.4          92.483          0                  0.99998            0.1
  **CCL3L1**     **17q12**             **610524**    7.6            8.675           106.2          1.037           69.425             0                  3.8                      88.9           35.98           0                  0.99998            −0.3
  **CCL2**       **17q12**             **1030333**   83.6           41.342          1064.4         209.641         83.693             0                  3.7                      290.2          135.327         **−34.545**        **0.00035**        **−1.9**
  **ADAMDEC1**   **8p21.2**            **1690192**   17.7           5.507           180.5          49.54           43.13              0.00005            3.4                      50.8           44.977          **−7.746**         **0.16803**        **−1.8**
  **ADAMDEC1**   **8p21.2**            **2470184**   45.6           28.138          457            160.361         21.198             0.00759            3.3                      113.9          76.87           −7.985             0.15903            −2.0
  **CNTNAP1**    **17q21.31**          **4570358**   6.7            7.157           64.5           10.33           33.995             0.0004             3.3                      74.2           11.383          0                  0.99998            0.2
  **IL8**        **4q13.3**            **1980309**   108.5          28.184          1007.9         353.371         21.558             0.00699            3.2                      134.5          78.161          **−6.288**         **0.23506**        **−2.9**
  **CCL3L1**     **17q12**             **4250053**   26.2           2.748           217.3          42.472          90.901             0                  3.1                      166.9          69.44           0                  0.99998            −0.4
  **SLAMF8**     **1q23.2**            **6040577**   28.3           16.329          207.3          71.669          18.141             0.01534            2.9                      42.3           37.615          **−9.425**         **0.11416**        **−2.3**
  **CD14**       **5q31.3**            **7000369**   27.7           15.637          197.5          58.132          28.835             0.00131            2.8                      131.4          27.984          0                  0.99998            −0.6
  **IL7R**       **5p13.2**            **3830349**   13.1           10.911          78             23.206          15.948             0.02542            2.6                      10.6           14.198          **−14.125**        **0.03868**        **−2.9**
  **SGK**        **6q23.2**            **4390450**   71.2           11.95           418            88.396          70.069             0                  2.6                      293.2          101.02          0                  0.99998            −0.5
  **CCL3L3**     **17q12**             **2810010**   79.2           10.877          460.5          26.218          108.993            0                  2.5                      391            123.518         0                  0.99998            −0.2
  **SGK1**       **6q23.2**            **1410209**   50.9           8.127           271.9          53.795          74.496             0                  2.4                      195.2          77.904          0                  0.99998            −0.5
  **SGK1**       **6q23.2**            **2030324**   51.9           1.156           246.2          53.282          56.057             0                  2.3                      173.7          60.625          0                  0.99998            −0.5
  **IL8**        **4q13.3**            **1570553**   66.3           3.606           310.1          46.316          86.246             0                  2.2                      134.5          78.161          −6.288             0.23506            −1.2
  **BCL3**       **19q13.31**          **6330725**   43.6           13.98           202.9          3.745           69.425             0                  2.2                      256.8          93.862          0                  0.99998            0.3
  **NFKB2**      **10q24.32**          **1710504**   22.1           8.518           101.9          7.329           42.738             0.00005            2.2                      123.9          32.161          0                  0.99998            0.3
  **MMP9**       **20q13.12**          **3180528**   72.3           17.171          324.8          73.222          48.888             0.00001            2.2                      41.4           17.344          **−58.228**        **0**              **−3.0**
  **IFI44L**     **1p31.1**            **3870338**   33.9           15.679          150.7          41.158          22.758             0.0053             2.2                      193.5          60.91           0                  0.99998            0.4
  **TNF**        **6p21.33**           **2640301**   202.2          71.993          869.5          212.143         35.423             0.00029            2.1                      731.9          321.682         0                  0.99998            −0.2
  **TLR8**       **Xp22.2**            **6480360**   28             11.682          117.2          25.951          33.995             0.0004             2.1                      31.4           18.932          **−18.749**        **0.01334**        **−1.9**
  **SPP1**       **4q22.1**            **3460070**   100.5          8.21            416.7          89.322          53.789             0                  2.1                      53.7           19.68           **−64.456**        **0**              **−3.0**
  **RGL1**       **1q25.3**            **3180039**   55.5           14.147          228.3          73.208          15.048             0.03128            2.0                      64.9           18.321          0                  0.99998            −1.8
  **CD83**       **6p23**              **6620026**   44.6           12.391          179.4          23.918          58.588             0                  2.0                      185.7          42.845          0                  0.99998            0.5
  **PLA2G4C**    **19q13.32**          **1990672**   192.8          30.83           766.4          102.941         88.184             0                  2.0                      661.2          289.94          0                  0.99998            −0.2
  **NFE2L3**     **7p15.2**            **5820035**   100.8          25.404          395.5          104.806         27.147             0.00193            2.0                      268.6          114.723         0                  0.99998            −0.6
  **TNFAIP3**    **6q23.3**            **3360681**   99.1           25.272          384.1          13.89           72.06              0                  2.0                      348.5          128.42          0                  0.99998            −0.1
  **SOD2**       **6q25.3**            **3420373**   124.4          25.642          469.7          153.48          12.912             0.05115            1.9                      297.2          186.744         0                  0.99998            −0.7
  **PMP22**      **17p12**             **7560138**   18.3           8.967           65.8           12.688          15.303             0.02949            1.9                      101.5          25.474          0                  0.99998            0.7
  **FEZ1**       **11q24.2**           **3290458**   387.3          24.881          1388.1         121.045         83.665             0                  1.8                      1156.9         230.953         0                  0.99998            −0.3
  **NFKB2**      **10q24.32**          **3310615**   24.4           8.507           85.9           14.941          25.951             0.00254            1.8                      112.6          18.106          0                  0.99998            0.4
  **EPSTI1**     **13q14.11-q14.11**   **5700725**   98.9           16.449          346.5          66.314          58.14              0                  1.8                      513.5          156.037         0                  0.99998            0.6
  **GPR84**      **12q13.13**          **2070646**   57.6           8.674           200.7          34.292          56.221             0                  1.8                      89.9           60.458          −3.008             0.50028            −1.2
  **RELB**       **19q13.32**          **730440**    50.5           7.492           173.3          23.16           51.233             0.00001            1.8                      181.2          56.865          0                  0.99998            0.1
  **MSC**        **8q13.3**            **7510377**   25.6           6.291           85.7           5.224           25.491             0.00282            1.7                      73.5           9.918           0                  0.99998            −0.2
  **FTH1**       **11q12.3**           **5220240**   501.6          130.423         1673.9         487.744         15.825             0.02615            1.7                      2232.1         993.713         0                  0.99998            0.4
  **NCF1**       **7q11.23**           **3940438**   320.9          93.979          1051.9         295.417         16.749             0.02114            1.7                      1328.8         323.479         0                  0.99998            0.3
  **NCF1C**      **7q11.23**           **3180681**   345.9          74.534          1114.1         163.744         67.61              0                  1.7                      1384.7         303.348         0                  0.99998            0.3
  **FEZ1**       **11q24.2**           **360427**    54.9           17.449          176.8          19.607          40.193             0.0001             1.7                      163.7          46.344          0                  0.99998            −0.1
  **OAS2**       **12q24.13**          **240722**    28             5.225           88.6           19.942          21.198             0.00759            1.7                      116.4          24.927          0                  0.99998            0.4
  **GBP2**       **1p22.2**            **1940162**   80.4           25.95           238.9          45.217          35.423             0.00029            1.6                      268.4          55.122          0                  0.99998            0.2
  **SOD2**       **6q25.3**            **3890326**   535            89.897          1585.9         213.363         65.492             0                  1.6                      1130.1         383.698         0                  0.99998            −0.5
  **ECGF1**      **22q13.33**          **7650128**   64.9           22.1            191.2          33.538          33.18              0.00048            1.6                      91.3           31.354          −9.698             0.1072             −1.1
  **MMP25**      **16p13.3**           **6020630**   33.7           6.297           97.3           3.732           23.134             0.00486            1.5                      53.5           8.542           −4.147             0.38489            −0.9
  **OAS3**       **12q24.13**          **990768**    80             19.678          230.2          43.56           38.675             0.00014            1.5                      366.1          91.638          1.296              0.74201            0.7
  **MX1**        **21q22.3**           **1690066**   890.6          376.587         2562.3         589.164         17.622             0.01729            1.5                      3602           1081.058        0                  0.99998            0.5
  **ZC3H12A**    **1p34.3**            **2490017**   57.7           14.209          165.5          16.804          35.386             0.00029            1.5                      186.3          25.133          0                  0.99998            0.2
  **IRF7**       **11p15.5**           **1470382**   52.1           17.993          149.1          33.814          18.858             0.01301            1.5                      156.6          29.869          0                  0.99998            0.1
  **CD83**       **6p23**              **5050162**   94.2           18.895          267.1          22.24           46.019             0.00003            1.5                      267.3          58.124          0                  0.99998            0.0

Data from those genes with scanning detection p-values ≤ 0.05, differentially express p-values ≤ 0.05 after FDR correction (Diff. p-val.), and Log-ratios ≥ 1.5 (regardless of the orientation) are shown. The differential scores (Diff. score) are a function of the p-values (Illumina Inc.). Log-ratios are the logarithm in base 2 of the average signal (AVG. sig.) ratios. We also show the array standard deviation of the average signals (Array_SD). NINT = Not infected not treated; YINT = Yes infected not treated; YIYT = Yes infected yes treated. We show highlighted in red the results from our primary targets. In black bold we show genes with scanning detection p-values ≤ 0.05, differentially express p-values ≤ 0.05 before FDR correction, and Log-ratios ≥ 1.5 (regardless of the orientation). All cultures proceed and were processed according to the protocols described in material and methods, including washing steps.

###### 

PAR-1 inhibitor treatment of infected THP-1 cells down-regulates MCP-1, MMP-1 and MMP-9 protein secretion, but does not modify *M. tuberculosis* intra-cellular proliferation

  Culture condition/measurement   *M. tuberculosis*- infected, untreated   *M. tuberculosis-* infected, treated   Two-sample t-test
  ------------------------------- ---------------------------------------- -------------------------------------- -------------------
  **MCP-1 (pg/ml ± SD)**          136 ± 39.7                               0                                      p = 0.004
  **MMP-1 (pg/ml ± SD)**          744.4 ± 103.4                            0                                      p \< 0.00001
  **MMP-9 (pg/ml ± SD)**          951 ± 23                                 0                                      p \< 0.0001
  **CFU/ml (10^3^)**              9 ± 2.65                                 8.3 ± 3.1                              ns

Soluble factors were determined in supernatants using ELISA test for MCP-1 (BD Biosciences) and functional specific-peptide-cleavage ELISA tests for MMP-1 and MMP-9 (R&D). Cell pellets lysed in Triton X-100 were used to recover intracellular bacteria and processed as indicated in material and methods to obtain the colony forming units (CFU) counts. SD = standard deviation; ns = not significant. The values for uninfected untreated negative control THP-1 cells were cero for MCP-1, MMP-1, and MMP-9.

[^1]: Dr. Pedro O. Flores-Villanueva and Dr. Malathesha Ganachari contributed equally to this work
